{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:43:03Z","timestamp":1791297783135,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:00:00Z","timestamp":1404172800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2014,7]]},"DOI":"10.1124\/jpet.114.214106","type":"journal-article","created":{"date-parts":[[2014,4,26]],"date-time":"2014-04-26T02:02:35Z","timestamp":1398477755000},"page":"130-143","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Macitentan Does Not Interfere with Hepatic Bile Salt Transport"],"prefix":"10.1016","volume":"350","author":[{"given":"Alexander","family":"Treiber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P\u00e4ivi","family":"\u00c4\u00e4nismaa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruben","family":"de Kanter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Delahaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianne","family":"Treher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Hess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Sidharta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.114.214106_bib1","doi-asserted-by":"crossref","first-page":"163","DOI":"10.3109\/00498250903509375","article-title":"Interaction of HIV protease inhibitors with OATP1B1, 1B3, and 2B1","volume":"40","author":"Annaert","year":"2010","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.114.214106_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s40262-013-0063-8","article-title":"Investigation of the effects of ketoconazole on the pharmacokinetics of macitentan, a novel dual endothelin receptor antagonist, in healthy subjects","volume":"52","author":"Atsmon","year":"2013","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/jpet.114.214106_bib3","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1046\/j.1523-1755.2000.00838.x","article-title":"Renal hemodynamics and pharmacokinetics of bosentan with and without cyclosporine A","volume":"57","author":"Binet","year":"2000","journal-title":"Kidney Int"},{"key":"10.1124\/jpet.114.214106_bib4","doi-asserted-by":"crossref","first-page":"7849","DOI":"10.1021\/jm3009103","article-title":"The discovery of N-[5-(4-bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N\u2032-propylsulfamide (Macitentan), an orally active, potent dual endothelin receptor antagonist","volume":"55","author":"Bolli","year":"2012","journal-title":"J Med Chem"},{"key":"10.1124\/jpet.114.214106_bib5","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2174\/0929867023371139","article-title":"Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications","volume":"9","author":"Boss","year":"2002","journal-title":"Curr Med Chem"},{"key":"10.1124\/jpet.114.214106_bib6","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1111\/j.1432-1033.1995.tb20696.x","article-title":"Separable binding sites for the natural agonist endothelin-1 and the non-peptide antagonist bosentan on human endothelin-A receptors","volume":"231","author":"Breu","year":"1995","journal-title":"Eur J Biochem"},{"key":"10.1124\/jpet.114.214106_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1208\/s12248-011-9316-3","article-title":"Effect of cyclosporine and rifampin on the pharmacokinetics of macitentan, a tissue-targeting dual endothelin receptor antagonist","volume":"14","author":"Bruderer","year":"2012","journal-title":"AAPS J"},{"key":"10.1124\/jpet.114.214106_bib8","doi-asserted-by":"crossref","first-page":"901","DOI":"10.3109\/00498254.2012.664665","article-title":"Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans","volume":"42","author":"Bruderer","year":"2012","journal-title":"Xenobiotica"},{"key":"10.1124\/jpet.114.214106_bib9","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1124\/dmd.111.040758","article-title":"In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans","volume":"40","author":"Dawson","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib10","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3851\/IMP1506","article-title":"Mutual pharmacokinetic interactions between bosentan and lopinavir\/ritonavir in healthy participants","volume":"15","author":"Dingemanse","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1124\/jpet.114.214106_bib11","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/B978-0-12-394316-3.00004-1","article-title":"The SLC10 carrier family: transport functions and molecular structure","volume":"70","author":"D\u00f6ring","year":"2012","journal-title":"Curr Top Membr"},{"key":"10.1124\/jpet.114.214106_bib12","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1067\/mcp.2001.114667","article-title":"The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions","volume":"69","author":"Fattinger","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.114.214106_bib13","first-page":"386","article-title":"Liver toxicity of sitaxentan in pulmonary arterial hypertension","volume":"32","author":"Gali\u00e8","year":"2011","journal-title":"Eur Heart J"},{"key":"10.1124\/jpet.114.214106_bib14","doi-asserted-by":"crossref","first-page":"10046","DOI":"10.1074\/jbc.273.16.10046","article-title":"The sister of P-glycoprotein represents the canalicular bile salt export pump of mammalian liver","volume":"273","author":"Gerloff","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1124\/jpet.114.214106_bib15","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discov"},{"key":"10.1124\/jpet.114.214106_bib16","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1124\/dmd.106.009290","article-title":"Drug-drug interaction between pitavastatin and various drugs via OATP1B1","volume":"34","author":"Hirano","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib17","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0091270008329550","article-title":"Lopinavir\/ritonavir pharmacokinetics in a substitution of high-dose soft-gelatin capsule to tablet formulation","volume":"49","author":"Hull","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.114.214106_bib18","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1183\/09031936.00138706","article-title":"Results of European post-marketing surveillance of bosentan in pulmonary hypertension","volume":"30","author":"Humbert","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1124\/jpet.114.214106_bib19","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1124\/jpet.108.142976","article-title":"Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist","volume":"327","author":"Iglarz","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.214106_bib20","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.clpt.2005.11.003","article-title":"Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics","volume":"79","author":"Katz","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.114.214106_bib21","doi-asserted-by":"crossref","first-page":"1878","DOI":"10.1124\/dmd.108.024778","article-title":"Effect of membrane cholesterol on BSEP\/Bsep activity: species specificity studies for substrates and inhibitors","volume":"37","author":"Kis","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib22","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1056\/NEJM199803193381202","article-title":"The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension","volume":"338","author":"Krum","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.214106_bib23","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1124\/jpet.106.119073","article-title":"Differential inhibition of rat and human Na+-dependent taurocholate cotransporting polypeptide (NTCP\/SLC10A1)by bosentan: a mechanism for species differences in hepatotoxicity","volume":"321","author":"Leslie","year":"2007","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.214106_bib24","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/bdd.527","article-title":"Effects of bosentan, an endothelin receptor antagonist, on bile salt export pump and multidrug resistance-associated protein 2","volume":"28","author":"Mano","year":"2007","journal-title":"Biopharm Drug Dispos"},{"key":"10.1124\/jpet.114.214106_bib25","doi-asserted-by":"crossref","first-page":"2467","DOI":"10.1021\/mp4000822","article-title":"Rapid measurement of intracellular unbound drug concentrations","volume":"10","author":"Mateus","year":"2013","journal-title":"Mol Pharm"},{"key":"10.1124\/jpet.114.214106_bib26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.111.187112","article-title":"Simultaneous assessment of uptake and metabolism in rat hepatocytes: a comprehensive mechanistic model","volume":"341","author":"M\u00e9nochet","year":"2012","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.214106_bib27","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1124\/dmd.105.008748","article-title":"Inhibition of bile acid transport across Na+\/taurocholate cotransporting polypeptide (SLC10A1) and bile salt export pump (ABCB 11)-coexpressing LLC-PK1 cells by cholestasis-inducing drugs","volume":"34","author":"Mita","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib28","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1124\/dmd.112.045872","article-title":"Commentary: theoretical predictions of flow effects on intestinal and systemic availability in physiologically based pharmacokinetic intestine models: the traditional model, segregated flow model, and QGut model","volume":"40","author":"Pang","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib29","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1056\/NEJMoa1213917","article-title":"Macitentan and morbidity and mortality in pulmonary arterial hypertension","volume":"369","author":"Pulido","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1124\/jpet.114.214106_bib30","first-page":"1066","article-title":"Macitentan, a tissue-targeting endothelin receptor antagonist for the potential oral treatment of pulmonary arterial hypertension and idiopathic pulmonary fibrosis","volume":"11","author":"Raja","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1124\/jpet.114.214106_bib31","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1002\/jps.20323","article-title":"Tissue distribution of basic drugs: accounting for enantiomeric, compound and regional differences amongst beta-blocking drugs in rat","volume":"94","author":"Rodgers","year":"2005","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.114.214106_bib32","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1002\/jps.20502","article-title":"Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions","volume":"95","author":"Rodgers","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/jpet.114.214106_bib33","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1007\/s11095-006-9210-3","article-title":"Mechanistic approaches to volume of distribution predictions: understanding the processes","volume":"24","author":"Rodgers","year":"2007","journal-title":"Pharm Res"},{"key":"10.1124\/jpet.114.214106_bib34","series-title":"Clinical Pharmacokinetics: Concepts and Applications","author":"Rowland","year":"1989"},{"key":"10.1124\/jpet.114.214106_bib35","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1124\/jpet.102.041921","article-title":"Inhibition of transporter-mediated hepatic uptake as a mechanism for drug-drug interaction between cerivastatin and cyclosporin A","volume":"304","author":"Shitara","year":"2003","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.214106_bib36","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/jcph.152","article-title":"Safety, tolerability, pharmacokinetics, and pharmacodynamics of macitentan, an endothelin receptor antagonist, in an ascending multiple-dose study in healthy subjects","volume":"53","author":"Sidharta","year":"2013","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/jpet.114.214106_bib37","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00228-011-1043-2","article-title":"Macitentan: entry-into-humans study with a new endothelin receptor antagonist","volume":"67","author":"Sidharta","year":"2011","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1124\/jpet.114.214106_bib38","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2010.120","article-title":"Potential for pharmacokinetic interactions between ambrisentan and cyclosporine","volume":"88","author":"Spence","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.114.214106_bib39","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/S0016-5085(00)70224-1","article-title":"Drug- and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt export pump (Bsep) of rat liver","volume":"118","author":"Stieger","year":"2000","journal-title":"Gastroenterology"},{"key":"10.1124\/jpet.114.214106_bib40","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1161\/01.CIR.98.21.2262","article-title":"Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure","volume":"98","author":"S\u00fctsch","year":"1998","journal-title":"Circulation"},{"key":"10.1124\/jpet.114.214106_bib41","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1124\/jpet.103.061614","article-title":"Inhibition of organic anion transporting polypeptide-mediated hepatic uptake is the major determinant in the pharmacokinetic interaction between bosentan and cyclosporin A in the rat","volume":"308","author":"Treiber","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/jpet.114.214106_bib42","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1124\/dmd.106.013615","article-title":"Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil","volume":"35","author":"Treiber","year":"2007","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib43","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1124\/dmd.105.004390","article-title":"The use of sandwich-cultured rat hepatocytes to determine the intrinsic clearance of compounds with different extraction ratios: 7-ethoxycoumarin and warfarin","volume":"33","author":"Treijtel","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib44","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1046\/j.1365-2125.2002.01608.x","article-title":"Single- and multiple-dose pharmacokinetics of bosentan and its interaction with ketoconazole","volume":"53","author":"van Giersbergen","year":"2002","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/jpet.114.214106_bib45","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.clpt.6100075","article-title":"Inhibitory and inductive effects of rifampin on the pharmacokinetics of bosentan in healthy subjects","volume":"81","author":"van Giersbergen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/jpet.114.214106_bib46","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1053\/jhep.2002.34133","article-title":"Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver","volume":"36","author":"Vavricka","year":"2002","journal-title":"Hepatology"},{"key":"10.1124\/jpet.114.214106_bib47","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1124\/dmd.112.047068","article-title":"Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification","volume":"40","author":"Warner","year":"2012","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib48","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1016\/S0090-9556(24)15230-0","article-title":"Absorption, excretion, and metabolism of the endothelin receptor antagonist bosentan in healthy male subjects","volume":"27","author":"Weber","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/jpet.114.214106_bib49","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.ejphar.2013.01.010","article-title":"Interaction profile of macitentan, a new non-selective endothelin-1 receptor antagonist, in vitro","volume":"701","author":"Weiss","year":"2013","journal-title":"Eur J Pharmacol"},{"key":"10.1124\/jpet.114.214106_bib50","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1517\/13543776.10.11.1653","article-title":"Recent discovery and development of endothelin receptor antagonists","volume":"10","author":"Wu","year":"2000","journal-title":"Expt Opin Ther Pat"},{"key":"10.1124\/jpet.114.214106_bib51","doi-asserted-by":"crossref","first-page":"676","DOI":"10.2174\/138920007782109733","article-title":"Prediction of intestinal first-pass drug metabolism","volume":"8","author":"Yang","year":"2007","journal-title":"Curr Drug Metab"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524187290?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524187290?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.114.214106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T12:42:57Z","timestamp":1739968977000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524187290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,7]]}},"alternative-id":["S0022356524187290"],"URL":"https:\/\/doi.org\/10.1124\/jpet.114.214106","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2014,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macitentan Does Not Interfere with Hepatic Bile Salt Transport","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.114.214106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2014 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}